NCT07702123 Efficacy of Physical Activity Program in Metabolic-syndrome Females With Behcet Disease
| NCT ID | NCT07702123 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cairo University |
| Condition | Metabolic Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-06-02 |
| Primary Completion | 2026-09-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2026-06-02 with a primary completion date of 2026-09-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
metabolci syndrom is highly prevalent in behcet disorder females. usually physical activity is recommended to solve this problem
Eligibility Criteria
Inclusion Criteria: * females with metabolci syndrome * females with behcet disorder Exclusion Criteria: * psychatric diseases women * mental diseased women
Contact & Investigator
Ali MA Ismail, lecturer
PRINCIPAL INVESTIGATOR
Cairo University
Frequently Asked Questions
Who can join the NCT07702123 clinical trial?
This trial is open to female participants only, aged 40 Years or older, up to 50 Years, studying Metabolic Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07702123 currently recruiting?
Yes, NCT07702123 is actively recruiting participants. Contact the research team at ali.mohamed@pt.cu.edu.eg for enrollment information.
Where is the NCT07702123 trial being conducted?
This trial is being conducted at Giza, Egypt.
Who is sponsoring the NCT07702123 clinical trial?
NCT07702123 is sponsored by Cairo University. The principal investigator is Ali MA Ismail, lecturer at Cairo University. The trial plans to enroll 40 participants.